Actively Recruiting
Randomized Study of Luspatercept Alone or With Epoetin Alfa in Adults with Lower-Risk Myelodysplastic Syndrome Without Ring Sideroblasts After ESA Failure or Ineligibility
Led by Groupe Francophone des Myelodysplasies · Updated on 2026-09-29
150
Participants Needed
41
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of luspatercept and erythropoiesis stimulating agents ESA for adults with lower-risk myelodysplastic syndrome LR-MDS without ring sideroblasts who have not responded to or are not eligible for ESA treatment. The trial is designed as a randomized Phase III study to determine the best dose and assess whether the combination is more effective than luspatercept alone. Participants receive luspatercept as a subcutaneous injection every three weeks, with doses adjusted in the dose-finding phase. In some groups, luspatercept is combined with weekly epoetin alfa Eprex injections at specified doses. The trial has two parts Part A focuses on finding the optimal dose for safety and effectiveness, and Part B compares the combination treatment to luspatercept alone in patients who did not respond or relapsed after ESA treatment. Throughout the study, participants undergo regular monitoring for toxicity and response at planned time points including evaluation of dose-limiting toxicities early on and assessing benefits by week 25. Secondary outcomes include response rate, duration of response, and overall survival tracked up to 30 months. The study requires adherence to scheduled visits and safety assessments, with informed consent and performance status evaluation at screening.
CONDITIONS
Brief Title
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Research Team
F
Fatiha CHERMAT
K
Karine LEMARIE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here